Kate Bak

TL;DR: Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptylines HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPn treatment options.

TL;DR: It is recommended that all patients with cancer be evaluated for symptoms of depression and anxiety at periodic times across the trajectory of care, and depending on levels of symptoms and supplementary information, differing treatment pathways are recommended.

TL;DR: This guideline presents screening, assessment, and treatment approaches for the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment and suggests physical activity interventions, psychosocial interventions, and mind-body interventions may reduce cancer-related fatigue in post-treatment patients.

TL;DR: No systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high‐risk, resected, primary melanoma, but high‐dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease‐free survival and a reduction in 2‐year mortality.

TL;DR: The review of the available literature suggests that temozolomide demonstrates comparable activity to the current standard treatment, dacarbazine, with the additional benefit of being a convenient oral treatment that penetrates the blood-brain barrier.